Q4 Revenue and Organic Growth
Q4 revenue of $536 million; total company organic growth of 2% in Q4 and 5% organic growth for full year 2025 (reported -14% in Q4 due to IV Solutions deconsolidation).
Record Operational Quarters
Both consumables and infusion systems delivered record operational revenue quarters in Q4, with consumables Q4 reported growth of 6% (5% organic) and full-year consumables growth of 7% reported / 6% organic.
Adjusted Gross Margin and Profitability
Adjusted gross margin of 40.5% in Q4 (above 40% target). Q4 adjusted EBITDA was $98 million and adjusted EPS was $1.91.
Progress on Regulatory and Product Roadmap
Official closure of the Smiths Medical FDA warning letter; continued progress on 510(k)s for Medfusion 5000 syringe pumps, CADD ambulatory pumps and LifeShield software — supporting a modernized, connected pump portfolio.
Operational Integrations Nearing Completion
Manufacturing integration of two large legacy Smiths Medical sites largely finished; Europe order-to-cash ERP conversion went live; these integrations expected to drive logistics, manufacturing and customer service synergies later in 2026.
Debt Reduction and Strong Cash Generation
Paid down $303 million principal in 2025; ended Q4 with $1.3 billion gross debt and $308 million cash (net debt ~ $1.0 billion); free cash flow of $44 million in Q4 and $100 million for FY2025; net leverage near 2.5x with a goal of 2.0x.
2026 Financial Guidance
Management expects 2026 consolidated organic revenue growth in the low- to mid-single-digit range; adjusted gross margin ~41%; adjusted EBITDA guidance of $400M–$430M and adjusted EPS of $7.75–$8.45; free cash flow expected to improve versus 2025 and be back-weighted to H2.
Product Mix and ASP Tailwind
Back-half 2026 pump unit growth expected to be weighted to higher-ASP Plum Duo and Plum Solo products, which should support revenue and improve hardware gross margin contribution over time.